Novo’s Wegovy® (semaglutide) reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat – EASD2026

Novo Nordisk A/S Novo reports analysis from STEP UP trial sub-population in which most participants with elevated liver fat achieved improved liver health after 72 weeks of Wegovy®(injectable semaglutide 7.2 and 2.4 mg) treatment. 9 in 10 achieved normal liver fat levels: Among participants with liver fat above 5%, 88.5% in the pooled group of people taking Wegovy® (injectable semaglutide 7.2 and 2.4 mg) achieved normal liver fat levels below 5% by week 72 Liver fat was reduced by nearly two-thirds: Measures showed liver fat declined from 8.8% to 3.